In the following course, PSMA-RLT was discontinued due to remission in 8/22 (36.4%) patients after a median of four cycles or ended by death in the remaining 14/22 (63.6%) patients due to eventual tumor progression after a median of seven cycles. This evidence concerns the gene FOLH1 and neoplasm.